LAURUSLABS · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 42/100 — Quality 57 · Valuation 16 · Growth 14 · Momentum 100
| Share price | ₹1,558.90 |
| Market cap | ₹58,088 Cr |
| P/E ratio | 69.0 |
| P/B ratio | 12.1 |
| ROE | 16.8% |
| ROCE | 11.9% |
| Dividend yield | 0.15% |
| Book value | ₹88.97 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹6,813 Cr | ₹890 Cr | 26.0% |
| 2025 | ₹5,554 Cr | ₹358 Cr | 19.0% |
| 2024 | ₹5,041 Cr | ₹162 Cr | 15.0% |
| 2023 | ₹6,041 Cr | ₹793 Cr | 26.0% |
| 2022 | ₹4,936 Cr | ₹832 Cr | 29.0% |
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions fo